Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PVLA vs ADPT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ADPT Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 4–4 Matrix Metrics)

ADPT Overall Winner 6-Pillar Tally: PVLA 2 – 4 ADPT Matrix Metrics: PVLA 4 – 4 ADPT

As of Nov 16, 2026, Adaptive Biotechnologies Corporation (ADPT) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). PVLA carries a Unified Composite Score of 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin), whereas ADPT carries 43.8/100 (HOLD) at $28.00 (N/M Forward P/E, -16.2% operating margin).

  • Composite vs. Pillar Nuance: While PVLA currently prints a higher short-term Unified Composite Score (48.2/100 HOLD vs. ADPT 43.8/100 HOLD), ADPT captures the overall institutional head-to-head verdict (4–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-16.2% vs. 0.0% operating margin) and revenue trajectory (-10.7% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PVLA vs ADPT
PVLA NASDAQ
Palvella Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$145.03
-4.89% 1D
Market Cap $2.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.66β · 75% Vol
Unified Composite Score
48.2 / 100 HOLD
Tech 35.0 Fund 53.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 50.9 · SMA20: $148.17 · SMA50: $143.42
ADPT NASDAQ Head-to-Head Winner
Adaptive Biotechnologies Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$28.00
-3.58% 1D
Market Cap $4.7B
TTM Revenue $298M
Forward P/E N/M
Beta / 30D Vol 1.75β · 60% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 15.0 Fund 43.0 Flow 69.0 Mom 54.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.2% over 20 days), RSI 52
RSI-14: 52.1 · SMA20: $27.26 · SMA50: $26.98

6-Pillar Scorecard Institutional Category Breakdown (PVLA 2 – 4 ADPT)

Columns: Metric · PVLA · ADPT
1. Valuation Multiples ADPT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 16.8x
2. Growth & Scale PVLA
Revenue Growth (YoY) +0.0% -10.7%
Earnings Growth (YoY) +0.0% -70.1%
TTM Revenue (USD) N/A $298M
Market Cap $2.2B $4.7B
3. Profitability & Quality PVLA
Gross Margin N/A 46.2%
Operating Margin 0.0% -16.2%
Net Profit Margin 0.0% -23.7%
Return on Equity (ROE) -63.4% -36.4%
4. Balance Sheet & Cash Flow ADPT
Cash Generation (TTM) -$43M -$8.8M
Cash Flow Margin N/A -3.0%
Net Cash / Leverage $193M Net Cash $333M Net Debt (2.32x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ADPT
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 47.9% (2nd %ile) 74.2% (32nd %ile)
Put/Call OI Skew 3.82x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat ADPT
OpEx & R&D Intensity N/A 62.4% of Rev ($186M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PVLA (4) vs ADPT (4)
Institutional Metric PVLA ADPT Criterion Row Edge
Market Capitalization
Scale
$2.2B $4.7B Larger Scale ADPT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -10.7% Higher Growth PVLA
Operating Margin (TTM)
Profitability
0.0% -16.2% Higher Margin PVLA
Net Profit Margin
Profitability
0.0% -23.7% Higher Margin PVLA
Return on Equity (ROE)
Capital Efficiency
-63.4% -36.4% Higher ROE ADPT
52-Week Range Position
Momentum
68% ($72–$180) 79% ($12–$32) Stronger Trend ADPT
Beta / 30D Volatility
Risk Regime
1.66β · 75% Vol 1.75β · 60% Vol Lower Realized Risk ADPT
Unified Institutional Score
Composite Signal
48.2 / 100 (HOLD) 43.8 / 100 (HOLD) Higher Composite PVLA
Trailing 12M Revenue (USD)
Operating Scale
N/A $298M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 46.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 16.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$43M ($193M Net Cash) -$8.8M ($333M Net Debt (2.32x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PVLA +3.99 pp
PVLA: +20.56% · ADPT: +16.57%
3M Horizon ADPT +17.59 pp
PVLA: -3.58% · ADPT: +14.01%
6M Horizon ADPT +82.24 pp
PVLA: +38.06% · ADPT: +120.3%
1Y Horizon ADPT +17.86 pp
PVLA: +80.16% · ADPT: +98.02%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PVLA Revenue ADPT Revenue PVLA Op. Margin ADPT Op. Margin Margin Leader
FY2018 $30M $60M -113.1% -89.4% ADPT
FY2019 $40M $90M -62.2% -92.1% PVLA
FY2020 $30M $100M -115.7% -155.3% PVLA
FY2021 $30M $150M -165.0% -135.4% ADPT
FY2022 $30M $190M -167.8% -108.0% ADPT
FY2023 $40M $170M -27.7% -133.3% PVLA
FY2024 N/A $180M N/A -90.8% ADPT
FY2025 N/A $280M N/A -20.6% ADPT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PVLA CONSOLIDATION
70d in phase · OBV DISTRIBUTION
Current IV 47.9%
IV Percentile 2nd %ile
Put/Call OI Skew 3.82x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PVLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ADPT CONSOLIDATION
69d in phase · OBV ACCUMULATION
Current IV 74.2%
IV Percentile 32nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ADPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PVLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ADPT Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $4.7B market capitalization and -16.2% operating margin.
OpEx & R&D Reinvestment 62.4% of Rev ($186M)
90D Engineering Disclosures 0 Published

Investor FAQ PVLA vs ADPT Key Questions & Quantitative Answers

As of Nov 16, 2026, Adaptive Biotechnologies Corporation (ADPT) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). PVLA carries a Unified Composite Score of 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin), whereas ADPT carries 43.8/100 (HOLD) at $28.00 (N/M Forward P/E, -16.2% operating margin). Composite vs. Pillar Nuance: While PVLA currently prints a higher short-term Unified Composite Score (48.2/100 HOLD vs. ADPT 43.8/100 HOLD), ADPT captures the overall institutional head-to-head verdict (4–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-16.2% vs. 0.0% operating margin) and revenue trajectory (-10.7% vs. +0.0% YoY).

PVLA leads the Growth & Scale pillar: PVLA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ADPT at -10.7% YoY revenue growth and -70.1% YoY earnings growth on $298M TTM revenue (46.2% gross margin, -16.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PVLA cumulative revenue shifted +33.3% while ADPT shifted +366.7%. In operating R&D and SG&A reinvestment, PVLA deploys N/A (0 90-day corporate R&D disclosures) versus 62.4% of Rev ($186M) (0 disclosures) for ADPT.

ADPT screens cheaper on headline valuation multiples. PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ADPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.8x EV/Revenue (-3.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PVLA (-63.4% ROE) versus ADPT (-36.4% ROE) capital efficiency.

In options market volatility and institutional positioning, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk). By comparison, ADPT carries 74.2% implied volatility (32nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.75β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.